A new oral anticoagulant drug is being trialled in patients with Deep Vein Thrombosis to see if there are less cases of intracerebral haemorrhage over 1 year compared with Rivaroxaban. 100 patients had the new drug and 5 of these patients had an intracerebral haemorrhage. A further 100 patients who were on Rivaroxaban over this timeframe had 1 patient from their cohort develop an intracerebral haemorrhage.
What is the risk ratio for the new drug?
